Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Accumulated Depreciation (2024 - 2025)

Maze Therapeutics has reported Accumulated Depreciation over the past 2 years, most recently at $19.2 million for Q4 2025.

  • Quarterly Accumulated Depreciation rose 13.9% to $19.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.2 million through Dec 2025, up 13.9% year-over-year, with the annual reading at $19.2 million for FY2025, 13.9% up from the prior year.
  • Accumulated Depreciation was $19.2 million for Q4 2025 at Maze Therapeutics, up from $16.9 million in the prior quarter.
  • Over five years, Accumulated Depreciation peaked at $19.2 million in Q4 2025 and troughed at $16.9 million in Q4 2024.